8 stories mentioning CTVAUpdated 43d ago
Every FINWIRES story that references CTVA, newest first.
Corteva (CTVA) has an average rating of overweight and mean price target of $88.38, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $82.86, Change: $+1.72, Percent Change: +2.12%
Corteva (CTVA) has an average rating of overweight and mean price target of $87.71, according to analysts polled by FactSet.Price: $80.03, Change: $-1.74, Percent Change: -2.13%
Corteva (CTVA) has an average rating of overweight and mean price target of $87.71, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $80.60, Change: $-1.16, Percent Change: -1.42%
Corteva (CTVA) has an average rating of overweight and mean price target of $86.33, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $81.41, Change: $-2.49, Percent Change: -2.97%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $84, 20.1x our 2027 EPS estimate, in line with CVTA's five-year average. After Q1 earnings release, we raise our 2026 EPS view to $4.01 from $3.72 to reflect the Q1 beat. We maintain our 2027 EPS estimate at $4.17. CTVA delivered strong Q1 2026 results today after market close, demonstrating robust operational execution across both business segments, while maintaining momentum toward the planned 2H 2026 separation of the Seed and Crop Protection business. Net sales increased to $4.9B (+11% Y/Y) with organic growth of 7% Y/Y, reflecting broad-based demand for the company's differentiated technology offerings across all geographic regions. Management confirmed the separation remains on track for 2H 2026, with key milestones including Luke Kissam's appointment as New Corteva CEO and the announcement of "Vylor" as the future seed and genetics company name. Yet, with shares up nearly 32% in the last six months, we see limited upside potential at this point and lower our rating to Hold from Buy.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Corteva delivered strong Q1 2026 results with operating EPS of $1.50 significantly exceeding consensus view of $1.18 (+33% Y/Y) and net sales of $4.9B (+11% Y/Y), $270M above expectations. Organic sales growth of 7% Y/Y reflected broad-based demand for differentiated technology offerings despite challenging agricultural conditions. The robust execution demonstrates management's ability to execute the separation strategy from a position of strength, with 6% global volume gains showcasing continued farmer adoption of advanced solutions. Management maintained the 2026 guidance with operating EBITDA of $4.0B-$4.2B and operating EPS of $3.45-$3.70, targeting Q4 2026 for separation completion. The Seed segment delivered exceptional performance with 34.2% operating EBITDA margins (+310 bps Y/Y), while Crop Protection maintained solid momentum with 23.1% margins (+101 bps Y/Y), reinforcing our view that both segments are well positioned for the planned separation with milestones progressing as expected.
Corteva (CTVA) reported Q1 adjusted earnings late Tuesday of $1.50 per diluted share, up from $1.13 a year earlier.Analysts polled by FactSet expected $1.17.Revenue in the three months ended March 31 rose to $4.91 billion from $4.42 billion a year earlier.Analysts surveyed by FactSet expected $4.64 billion.The company expects full-year operating EPS of $3.45 to $3.70. Analysts expect $3.66.Corteva shares fell 2% in after-hours trading.
Corteva Inc (CTVA) has an average rating of overweight and mean price target of $86.19, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $79.55, Change: $+0.61, Percent Change: +0.77%
